Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Finalizing Notice-To-Industry Policy, Amid Concerns

This article was originally published in The Gray Sheet

Executive Summary

Device makers see benefit in FDA’s plan to issue “notice to industry” letters when it wants to communicate policy changes quickly, but industry reps emphasize that FDA should not overuse the approach.

You may also be interested in...

CDRH Tries Again On Proposal For Rapidly Communicating Policy Changes

FDA’s device center has dropped previously proposed “notice-to-industry letter” terminology and abandoned the idea of sending out rapid-fire communications in anything but official guidance format in its new draft standard operating procedures on “Level 1 – immediately in effect” guidance. The document updates a 2011 SOP that faced pushback from companies.

FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance

FDA says some of its new "notice-to-industry" letters will have the same force as agency guidance documents that take effect immediately.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts